Purpose of Review <p>Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer characterized by rapid progression of local disease and development of distant metastasis. Despite advances in treatment strategies, inflammatory breast cancer carries a worse prognosis compared to non-inflammatory locally advanced breast cancers. The aim of this report is to provide an overview on the management of inflammatory breast cancer.</p> Recent Findings <p>Advances in tri-modality therapy continue to result in improved prognosis in patients with IBC. However, rates of overall survival and disease-free survival remain lower than in patients with non-inflammatory, locally advanced breast cancer. Due to increasing rates of pathologic complete response to neoadjuvant chemotherapy, there is ongoing discussion regarding de-escalation of surgery in certain patients with inflammatory breast cancer. Though recent studies are promising, modified radical mastectomy remains the standard of care for surgical treatment of inflammatory breast cancer.</p> Summary <p>Tri-modality therapy with neoadjuvant systemic therapy, modified radical mastectomy, and post-mastectomy radiation therapy has resulted in improved rates of locoregional control and overall survival in IBC patients. Breast conservation surgery or sentinel lymph node biopsy techniques are not recommended in the treatment of IBC.</p>